Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant Gram-positive organisms

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 3, 1997, Pages 423-425

  Fraise, A P ^a   Andrews, J ^a   Wise, R ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; GENTAMICIN; GLYCOPEPTIDE; ORITAVANCIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE;

AMPICILLIN; ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENTAMICINS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; TEICOPLANIN; VANCOMYCIN;

EID: 0030821696     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.3.423     Document Type: Article

References (10)

1. Nicas T. I. & Cooper, R. D. G. (1995). Activity of novel semi-synthetic glycopeptides against vancomycin resistant enterococi. In Program and Abstracts of the 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, 1995. Abstract 560. European Society of Clinical Microbiology and Infectious Diseases.
2. Lin, Y., Stratford, R. E., Zornes, L. L., Confer, W. L., Vasudevan, V., Jones, T. W. et al. (1995). Non-clinical pharmacokinetics of LY333328, a semisynthetic glycopeptide antibiotic active against vancomycin-resistant enterococci. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F254, p. 157. American Society for Microbiology, Washington, DC.
3. Schwalbe, R. S., McIntosh, A. C., Qaiyumi, S., Johnson, J. A., Johnson, R. J., Furness, K. M. et al. (1996). In vitro activity of LY333328 an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrobial Agents and Chemotherapy 40, 2416-9.
4. Moellering, R. C. (1992). Emergence of Enterococcus as a significant pathogen. Clinical Infectious Diseases 14, 1173-6.
5. Handwerger, S., Raucher, B., Altarac, D., Monka, J., Marchione, S., Singh, K. V. et al. (1993). Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin and gentamicin. Clinical Infectious Diseases 16, 750-5.
6. Goldstein B. P., Candiani, G., Arain, T. M., Romano, G., Ciciliato, I., Berti, M. et al. (1995) Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrobial Agents and Chemotherapy 39, 1580-8
7. Nicas T. I, Mullen, D. L., Flokowitsch, J. E., Preston, D. A., Snyder N. J., Stratford, R. E. et al. (1995). Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 39, 2585-7
8. Nicas T. I., Mullen, D. L, Flokowitsch, J. E., Preston, D. A., Snyder, N. J., Zweifel, M. J. et al. (1996). Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrobial Agents and Chemotherapy 40, 2194-9.
9. Allen, N. E., Hobbs, J. N. & LeTourneau, D. L. (1996). The role of ligand binding, dimerisation and membrane interactions in the antibacterial action of glycopeptide antibiotics. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract C12, p. 36. American Society for Microbiology, Washington, DC.
10. Arthur, M. & Courvalin, P. (1993). Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrobial Agents and Chemotherapy 37, 1563-71.